These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 6897355)

  • 1. Effects of the xanthine oxidase inhibitor allopurinol on the renal clearance of nitroimidazoles.
    Workman P; White RA
    Biochem Pharmacol; 1982 Oct; 31(19):3041-6. PubMed ID: 6897355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and tumour-penetration properties of the hypoxic cell radiosensitizer desmethylmisonidazole (Ro 05-Ro-9963) in dogs.
    White RA; Workman P
    Br J Cancer; 1980 Feb; 41(2):268-76. PubMed ID: 7370166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-dependence and related studies on the pharmacokinetics of misonidazole and desmethylmisonidazole in mice.
    Workman P
    Cancer Chemother Pharmacol; 1980; 5(1):27-37. PubMed ID: 7460192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-pharmacokinetic relationships for misonidazole analogues in mice.
    Workman P; Brown JM
    Cancer Chemother Pharmacol; 1981; 6(1):39-49. PubMed ID: 7273265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonlinear pharmacokinetics of misonidazole and desmethylmisonidazole in the isolated perfused rat liver.
    McManus ME; Monks A; Collins JM; White R; Strong JM
    J Pharmacol Exp Ther; 1981 Dec; 219(3):669-74. PubMed ID: 7299690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-function dependence and allopurinol inhibition of radiosensitizer/nitroreductase interaction: approaches to improving therapeutic ratios.
    Raleigh JA; Shum FY; Koziol DR; Saunders WM
    Cancer Clin Trials; 1980; 3(1):55-62. PubMed ID: 6771029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered pharmacokinetics in the mechanism of chemosensitization: effects of nitroimidazoles and other chemical modifiers on the pharmacokinetics, antitumour activity and acute toxicity of selected nitrogen mustards.
    Lee FY; Workman P
    Cancer Chemother Pharmacol; 1986; 17(1):30-7. PubMed ID: 3698174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of the metabolism-induced binding of misonidazole to hypoxic mammalian cells.
    Chapman JD; Baer K; Lee J
    Cancer Res; 1983 Apr; 43(4):1523-8. PubMed ID: 6831401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and toxicology of continuously infused nitroimidazoles.
    Eifel PJ; Brown JM
    Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1311-4. PubMed ID: 6236186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the fate of misonidazole (RO 07-0582) and its metabolite desmethylmisonidazole (RO 05-9963), two hypoxic cell radiosensitizers: penetration properties in tumor bearing rats.
    Akel G; Canal P; Mockey E; Vandevoorde E; Laurent F; Soula G
    J Pharmacol; 1983; 14(1):67-77. PubMed ID: 6834852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of cimetidine, antipyrine, and pregnenolone carbonitrile on misonidazole pharmacokinetics.
    Workman P; Donaldson J; Smith NC
    Cancer Treat Rep; 1983; 67(7-8):723-5. PubMed ID: 6871889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacokinetics in mice and dogs of nitroimidazole radiosensitizers and chemosensitizers more lipophilic than misonidazole.
    White R; Workman P; Owen L
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):473-6. PubMed ID: 7107369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modification of CCNU pharmacokinetics by misonidazole--a major mechanism of chemosensitization in mice.
    Lee FY; Workman P
    Br J Cancer; 1983 May; 47(5):659-69. PubMed ID: 6849803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of misonidazole and its derivatives by xanthine oxidase.
    Josephy PD; Palcic B; Skarsgard LD
    Biochem Pharmacol; 1981 Apr; 30(8):849-53. PubMed ID: 6894696
    [No Abstract]   [Full Text] [Related]  

  • 15. The role of dexamethasone in the modification of misonidazole pharmacokinetics.
    Jones DH; Bleehen NM; Workman P; Walton MI
    Br J Cancer; 1983 Oct; 48(4):553-7. PubMed ID: 6626454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative study on the hypouricemic activity and potency in renal xanthine calculus formation of two xanthine oxidase/xanthine dehydrogenase inhibitors: TEI-6720 and allopurinol in rats.
    Horiuchi H; Ota M; Kobayashi M; Kaneko H; Kasahara Y; Nishimura S; Kondo S; Komoriya K
    Res Commun Mol Pathol Pharmacol; 1999; 104(3):307-19. PubMed ID: 10741381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of vitamin B6 on the neurotoxicity and pharmacology of desmethylmisonidazole and misonidazole: clinical and laboratory studies.
    Coleman CN; Hirst VK; Brown DM; Halsey J
    Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1381-6. PubMed ID: 6469761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of specific reductases in the intracellular activation and binding of 2-nitroimidazoles.
    Joseph P; Jaiswal AK; Stobbe CC; Chapman JD
    Int J Radiat Oncol Biol Phys; 1994 May; 29(2):351-5. PubMed ID: 8195032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paraxanthine metabolism in humans: determination of metabolic partial clearances and effects of allopurinol and cimetidine.
    Lelo A; Kjellen G; Birkett DJ; Miners JO
    J Pharmacol Exp Ther; 1989 Jan; 248(1):315-9. PubMed ID: 2913277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of whole body hyperthermia on the pharmacokinetics and toxicity of the basic 2-nitroimidazole radiosensitizer Ro 03-8799 in mice.
    Walton MI; Bleehen NM; Workman P
    Br J Cancer; 1987 May; 55(5):469-76. PubMed ID: 3606940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.